Stock analysis · Bull Rankings model

ATEC analysis

Alphatec Holdings, Inc.Medical Devices. Scored on the same transparent model behind the daily rankings.

ATEC
Alphatec Holdings, Inc. · Medical Devices
FCF$7mC-
Rev+22.5%A-
D/E
P/S2.0xB+
PEG0.48A
64Score
$10.15$1.6B
1Y Target$15.86Analyst consensus · 14 analysts
5Y Target$27.73Compound horizon
10Y Target$49.57Long-dated conviction
FCF$7mTTM
C-
FCF $7m — barely positive; fragile cash position
Rev+22.5%TTM YoY
A-
Revenue +22.5% — strong growth, well above S&P median (~7%)
D/E
D/E data unavailable — neutral default
P/S2.0x
B+
P/S 2.0x — below the Healthcare median (≈40th pctile)
PEG0.48
A
PEG 0.48 — exceptional; paying well under fair value for growth

Forward price target — the 1-year figure is the analyst consensus where the stock is covered; the 5- and 10-year figures compound our earnings estimate from there. The DCF below is a separate cross-check on intrinsic value (what it's worth today), not another target.

Quality-growth score · 64
Quality0.36
Growth1.00
Value0.74
Why this score
  • Diluting shareholders
  • Short track record
Entry · Margin of safety
52-week rangeNear 52-week low
56% off the 12-month high
vs DCF fair value745% aboveest. fair value ~$1
What the price assumes: free cash flow compounding above 60% a year for the next decade — vs the ~25% a year our model projects from current growth and analyst estimates.
Quality signals · context only
Gross profitability69% · Agross profit ÷ total assets (Novy-Marx)
Why now
Medical Devices · market cap $1.6b. Down 56% from 52-week high of $23.29 — deep drawdown territory. Revenue growing +23%, comfortably above the S&P median. PEG 0.48 — paying under fair value for the growth rate. 14 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $15.86 (implying +56% upside).
Moat
Turnaround / out-of-favor name — GAAP-unprofitable for now, so the durability case is forward-looking: it rests on a recovery (margin normalization, a cyclical upturn or restructuring) or an un-monetized asset (IP / network effects / first-mover position) rather than on current reported results.
Risk
Currently unprofitable (margin -15.9%) — path to GAAP profitability is the core thesis risk. Down 56% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Horizon
1-3 yr $15.86 (14-analyst consensus) — catalyst-driven; binary events dominate. 5 yr $27.73 — requires the platform / technology to reach commercial scale. 10 yr $49.57 — return distribution heavily skewed.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.

ATEC vs the Top Picks average

PillarATECBook avgDiff
Quality0.360.83-0.47
Growth1.000.91+0.09
Value0.740.75in line

Averaged across the 30 names in today's Top Picks (mean score 81.8). A name can beat these averages and still be absent from the book — it also applies concentration limits.

Trend
-0.4 over 7 daily scores
From 64.4 (Jun 22) → 64.0 (now)

One point per daily model run. The range autoscales, so a flat-looking line can still hide 1–2 point moves — read the From → To values for the actual range.

Shares to buy
197
Position size
$2,000
4.0% of portfolio
Stop price
$7.61
25% below $10.15
$ at risk if stopped
$499.89
budget $500.00 · 1% of portfolio

Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.

Latest ATEC developments

Recent headlines from across the financial press · updated daily. Links open the source.

Alphatec Holdings, Inc. (ATEC): score, valuation & FAQ

Alphatec Holdings, Inc. (ATEC) is a Medical Devices company that scores 64 out of 100 on the Bull Rankings quality-growth model — a solid, above-average reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.

Its strongest graded signals are PEG (A), Rev (A-) and P/S (B+), while FCF (C-) rate weaker. On valuation, ATEC sits about 745% above our discounted-cash-flow fair value — the current price implies free-cash-flow growth above 60% a year for the next decade.

Is ATEC a good stock to buy?

Bull Rankings scores ATEC 64 out of 100 on its quality-growth model, which is a solid, above-average reading. That is driven by PEG (A), Rev (A-) and P/S (B+). A score is a quantitative screen of Alphatec Holdings, Inc.'s fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.

Why does ATEC score 64 on Bull Rankings?

The quality-growth score blends three pillars — quality (returns on capital, margins, leverage, earnings quality), growth (revenue and earnings expansion), and value (valuation versus sector peers). ATEC earns its highest marks on PEG (A), Rev (A-) and P/S (B+), and is held back by FCF (C-). Each pillar is graded against sector-aware thresholds, then combined into the single 0–100 score.

Is ATEC overvalued or undervalued?

Based on $10.15, ATEC sits about 745% above our discounted-cash-flow fair value — the current price implies free-cash-flow growth above 60% a year for the next decade. Discounted-cash-flow estimates are sensitive to growth and discount-rate assumptions, so treat this as a cross-check, not a price target.

What are the main risks of investing in ATEC?

Currently unprofitable (margin -15.9%) — path to GAAP profitability is the core thesis risk. Down 56% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.

New to these metrics? The guides explain free cash flow, how the score works, and more in the learn hub — or run another name through the screener.

Bull Rankings is an automated fundamentals screen for research and education. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a licensed financial adviser.

More Medical Devices & Diagnostics stocks by score

All Healthcare rankings →

Analyze another ticker →